MXPA05013900A - Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension. - Google Patents

Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension.

Info

Publication number
MXPA05013900A
MXPA05013900A MXPA05013900A MXPA05013900A MXPA05013900A MX PA05013900 A MXPA05013900 A MX PA05013900A MX PA05013900 A MXPA05013900 A MX PA05013900A MX PA05013900 A MXPA05013900 A MX PA05013900A MX PA05013900 A MXPA05013900 A MX PA05013900A
Authority
MX
Mexico
Prior art keywords
stress
brimonidine
severity
preventing
reducing
Prior art date
Application number
MXPA05013900A
Other languages
English (en)
Inventor
Mitchell F Brin
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33540268&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05013900(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MXPA05013900A publication Critical patent/MXPA05013900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion proporciona un metodo para prevenir o reducir la severidad de una condicion asociada con la tension en un sujeto administrando sistemicamente al sujeto una cantidad efectiva de brimonidina o una sal, ester, amida, estereoisomerico o mezcla racemica farmaceuticamente aceptable de la misma. Las condiciones asociadas con la tension que pueden ser tratadas de acuerdo a un metodo de la invencion incluyen, pero no se limitan a, la dispepsia, taquicardias diferentes a las taquicardias asociadas con la isquemia miocardiaca, ataque de panico, condiciones dermatologicas no inflamatorias, trastornos de la contraccion muscular, hipersensibilidad sensorial asociada con la migrana y trastornos de comportamiento.
MXPA05013900A 2003-06-25 2004-06-22 Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension. MXPA05013900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/607,439 US20040266776A1 (en) 2003-06-25 2003-06-25 Methods of preventing and reducing the severity of stress-associated conditions
PCT/US2004/020194 WO2005002580A1 (en) 2003-06-25 2004-06-22 Use of brimonidine for preventing and reducing the severity of stress-associated conditions

Publications (1)

Publication Number Publication Date
MXPA05013900A true MXPA05013900A (es) 2006-02-24

Family

ID=33540268

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013900A MXPA05013900A (es) 2003-06-25 2004-06-22 Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension.

Country Status (15)

Country Link
US (6) US20040266776A1 (es)
EP (1) EP1638569B1 (es)
JP (2) JP2007524625A (es)
KR (1) KR20060023575A (es)
CN (2) CN1812791A (es)
AT (1) ATE539751T1 (es)
AU (2) AU2004253500A1 (es)
BR (1) BRPI0411826A (es)
CA (1) CA2530487C (es)
DK (1) DK1638569T3 (es)
ES (1) ES2376878T3 (es)
HK (1) HK1090282A1 (es)
MX (1) MXPA05013900A (es)
TW (1) TWI371276B (es)
WO (1) WO2005002580A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
US6699493B2 (en) 2000-11-29 2004-03-02 Oculex Pharmaceuticals, Inc. Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050059744A1 (en) * 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
US20100266638A1 (en) 2004-02-26 2010-10-21 Allergan, Inc. Headache treatment method
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
PL1761266T3 (pl) * 2004-05-25 2013-09-30 Galderma Pharma Sa Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
WO2008144399A1 (en) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated COMPLEXES COMPRISING α2-ADRENERGIC RECEPTOR AGONISTS AND COMPOSITIONS
US20090060852A1 (en) * 2007-07-27 2009-03-05 Jack Dejovin Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
WO2009052073A2 (en) 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
WO2009052071A1 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Treatment of sensorimotor disorders with 4- ( 1- ( 2, 3 -dimethylphenyl) ethyl) -1h-imidaz0le-2 ( 3h) -thione
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
US20100029662A1 (en) 2008-08-01 2010-02-04 Alpha Synergy Development, Inc. Vasoconstriction compositions and methods of use
US20100203165A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
WO2011028621A1 (en) * 2009-08-26 2011-03-10 Allergan, Inc. Method of treating compulsive disorders with alpha-2b adrenergic receptor agonists
KR20170095402A (ko) 2009-11-09 2017-08-22 알러간, 인코포레이티드 모발 성장을 촉진하기 위한 조성물 및 방법
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CA2782872A1 (en) * 2009-12-17 2011-06-23 Alpha Synergy Development, Inc. Compositions and methods for ophthalmic delivery of nasal decongestants
DK2552449T3 (en) 2010-03-26 2017-06-19 Galderma Res & Dev COMPOSITIONS INCLUDING BRIMONIDINE FOR TREATMENT OF ERYTHEM
KR20150058551A (ko) 2010-03-26 2015-05-28 갈데르마 리써어치 앤드 디벨로프먼트 모세혈관 확장증의 안전하고 유효한 치료를 위한 개선된 방법 및 조성물
US20120073515A1 (en) * 2010-09-28 2012-03-29 Advanced Bionics Corporation Intrathecal needle guide apparatus
CA2814952C (en) 2010-10-21 2016-05-10 Galderma S.A. Brimonidine gel compositions and methods of use
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US8445526B2 (en) 2011-02-03 2013-05-21 Glaucoma & Nasal Therapies Llc Compositions and methods for treatment of glaucoma
US9144600B2 (en) 2011-07-14 2015-09-29 Allergan, Inc. Methods for treatment of incontinence associated with sexual activity
CA2901280A1 (en) 2013-02-15 2014-08-21 Allergan, Inc. Sustained drug delivery implant
US8999938B2 (en) 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
EP3226972A4 (en) 2014-12-01 2018-08-08 Achelios Therapeutics, Inc. Methods and compositions for treating migraine and conditions associated with pain
US20210188817A1 (en) * 2018-08-29 2021-06-24 Cellix Bio Private Limited Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5380754A (en) * 1988-02-29 1995-01-10 Virotex Corporation Topical composition enhancing healing of viral lesions
EP1285657A3 (en) * 1993-10-13 2003-08-20 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6462077B1 (en) * 1993-12-28 2002-10-08 Allergan, Inc. Thromboxane ligands without blood clotting side effects
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
WO1996025163A1 (en) 1995-02-14 1996-08-22 Board Of Supervisors Or Louisiana State Universityof Agricultural And Mechanical College Through Itsmedical Center Treatment of herpes simplex viruses
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
WO1999030690A1 (en) 1997-12-15 1999-06-24 Axia Therapeutics, Inc. Oral delivery formulation
US20030059471A1 (en) * 1997-12-15 2003-03-27 Compton Bruce Jon Oral delivery formulation
PT1124535E (pt) 1998-10-27 2003-04-30 Alcon Lab Inc Sistema conservante para composicoes farmaceuticas topicamente administraveis contendo um sabao de acido gordo/amino acido
MXPA01012187A (es) * 1999-05-28 2002-06-21 Jeffrey Berlant Compuestos y metodos para el tratamiento del trastorno por estres postraumatico.
WO2000076502A1 (en) 1999-06-11 2000-12-21 The Ohio State University Research Foundation Methods and compositions for treating raynaud's phenomenon and scleroderma
KR100331529B1 (ko) 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법
US7160890B2 (en) * 1999-12-02 2007-01-09 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
IN188750B (es) 1999-12-04 2002-11-02 Khamar Bakulesh Dr Mafatlal
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6444681B1 (en) * 2000-06-09 2002-09-03 The Ohio State University Research Foundation Methods and compositions for treating Raynaud's Phenomenon and scleroderma
IL151530A0 (en) * 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
CA2468673C (en) 2001-11-30 2011-01-25 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 and a3 receptors and uses thereof
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7345065B2 (en) * 2002-05-21 2008-03-18 Allergan, Inc. Methods and compositions for alleviating pain
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
PL1761266T3 (pl) 2004-05-25 2013-09-30 Galderma Pharma Sa Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry

Also Published As

Publication number Publication date
AU2004253500A1 (en) 2005-01-13
AU2010241513B9 (en) 2011-10-20
CN1812791A (zh) 2006-08-02
HK1090282A1 (en) 2006-12-22
CA2530487C (en) 2011-11-01
JP2007524625A (ja) 2007-08-30
US20130102612A1 (en) 2013-04-25
ATE539751T1 (de) 2012-01-15
TW200524611A (en) 2005-08-01
US20120302574A1 (en) 2012-11-29
DK1638569T3 (da) 2012-04-02
CN102579448A (zh) 2012-07-18
CA2530487A1 (en) 2005-01-13
US7977335B2 (en) 2011-07-12
EP1638569A1 (en) 2006-03-29
AU2010241513B2 (en) 2011-09-22
US20080207627A1 (en) 2008-08-28
US20130217694A1 (en) 2013-08-22
EP1638569B1 (en) 2012-01-04
ES2376878T3 (es) 2012-03-20
WO2005002580A1 (en) 2005-01-13
BRPI0411826A (pt) 2006-08-08
AU2010241513A1 (en) 2010-12-09
US20040266776A1 (en) 2004-12-30
JP2012092123A (ja) 2012-05-17
TWI371276B (en) 2012-09-01
KR20060023575A (ko) 2006-03-14
US20080207628A1 (en) 2008-08-28

Similar Documents

Publication Publication Date Title
MXPA05013900A (es) Uso de brimonidina para prevenir y reducir la severidad de condiciones asociadas con la tension.
WO2004108157A8 (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders
WO2007112345A3 (en) Use of cyclosporin alkene analogues for preventing or treating viral-induced disorders
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
WO2005092009A3 (en) Acetylcholinesterase inhibitors and n-methyl-d-aspartate antagonists useful in the treatment of cognitive disorders
WO2007112352A3 (en) Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2007129195A3 (en) 4-pyrimidine-5-amino-pyrazole compounds
WO2006113498A3 (en) 2-amino-quinaz0lin-5-ones as hsp90 inhibitors useful in treating proliferation diseases
WO2004041188A3 (en) Compositions and methods for transdermal oxybutynin therapy
WO2004089353A3 (en) Methods for treatment of parkinson's disease
MXPA05010185A (es) Metodos para tratar o prevenir un estado inflamatorio o metabolico por inhibicion de jnk.
MX2010005343A (es) Compuestos indola 3, 5-sustituidos que tienen actividad inhibidora de la re-absorcion y el reciclo de nos y norepinefrina.
HK1107084A1 (en) 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h-pyridoÄ2,3-dÜpyrimidine derivatives and related compoundsfor the treatment of cancer
WO2006105117A3 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
TN2011000228A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
WO2018060463A3 (en) Treatment of prostate cancer
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
WO2012021818A3 (en) Ggf2 and methods of use
WO2018231718A8 (en) Dermal filler
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
WO2005120148A3 (en) Compounds derived from lidocaine, pharmaceutical compositions, use and method of treatment, prevention or inhibition of diseases
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
WO2005037230A3 (en) Compositions and methods for treating heart failure
WO2010045582A3 (en) Compositions and methods for treating or preventing hypoxic or ischemic injury
CA2425812A1 (en) Treatment of oppositional defiant disorder and conduct disorder with 5-amino-4,5,6,7-tetrahydro-4-oxyindolones

Legal Events

Date Code Title Description
FG Grant or registration